Why Generic Translation Vendors Fail LATAM Regulatory Submissions

Most translation vendors deliver grammatically correct, terminologically consistent documents. By every standard metric of translation quality, the work passes.

And then the regulator sends it back.

This happens because regulatory translation in Latin America is not a language problem. It is a regulatory intelligence problem. The translator needs to know not just what the words mean, but what the regulator expects to see, how they interpret specific terminology, and what formatting conventions trigger a request for information versus a clean acceptance.

A generic translation vendor, no matter how experienced in medical or life sciences translation, does not have this information. They translate the document. They do not translate the regulatory intent.

Each LATAM regulatory authority has its own interpretation framework. ANVISA in Brazil, COFEPRIS in Mexico, INVIMA in Colombia, ANMAT in Argentina, DIGEMID in Peru, ISP in Chile, ARCSA in Ecuador, DNM in Paraguay, and SRS in the Dominican Republic all review submissions in their local language, but they do not all read the same way.

COFEPRIS has specific expectations for how a device's intended use is described. A translation that uses a clinically accurate but non-standard term will generate an RFI. Not because the translation is wrong, but because it does not match the terminology COFEPRIS uses internally.

ANVISA requires sworn translations for most technical documents. A certified translation, even from a qualified medical translator, will be rejected on procedural grounds before the science is ever reviewed.

INVIMA flags inconsistencies between the device description in the technical summary and the device description in the instructions for use. If the translator used slightly different phrasing in each document, that discrepancy becomes a formal observation.

These are not edge cases. They are the most common reasons submissions lose 60 to 120 days.

Sponsors typically select translation vendors based on three criteria: language pair coverage, turnaround time, and cost per word. These are reasonable procurement metrics for general translation. They are insufficient for regulatory translation.

The missing criterion is regulatory submission experience with the specific authority reviewing the dossier. Not medical translation experience. Not life sciences experience. Specific, documented experience with how COFEPRIS reviews device submissions versus how ANMAT reviews them versus how DIGEMID reviews them.

A vendor who has translated 10,000 medical documents but never seen an RFI from INVIMA does not know what INVIMA flags. They cannot prevent a rejection they have never encountered.

A translation-triggered RFI does not just delay the submission by the time it takes to fix the translation. It resets the review clock. In most LATAM jurisdictions, the regulator stops the review timer when they issue an RFI and restarts it only when the sponsor responds with a compliant correction.

In practice, a single translation error can add 60 to 120 days to a submission timeline. Multiply that across a multi-country filing and the cumulative delay can push a product launch back by six months or more.

The sponsor pays for the original translation, the RFI response, the corrected translation, and the opportunity cost of the delay. The total cost of a cheap translation is almost always higher than the cost of doing it right the first time.

Regulatory translation for LATAM submissions requires four capabilities that generic vendors typically do not offer:

1. Regulator-specific terminology mapping. Each authority has preferred terms for common regulatory concepts. A translation partner needs a maintained glossary per regulator, updated with every submission cycle.

2. Document-type routing. Different documents require different translation types (sworn versus certified) depending on the country and the document category. The translation partner needs to know the routing rules before the project starts, not after the regulator rejects the filing.

3. Cross-document consistency validation. Regulators compare terminology across the entire dossier. The device description in the technical summary must match the device description in the IFU, the labeling, and the certificate of free sale. A translation partner needs a systematic cross-referencing process, not just per-document QC.

4. Physician-led medical review. For clinical documents like informed consent forms, protocols, and clinical study reports, the translation must be reviewed by a physician who understands both the clinical content and the local patient population. A linguist cannot catch a clinically misleading translation. A physician can.

At Amavita Sciences™, we built our entire workflow around the reality that LATAM regulatory translation is not a language service. It is a regulatory submission service that happens to involve language.

Every project starts with a regulatory routing assessment: which countries, which authorities, which document types, which translation types required, which terminology conventions apply. This mapping happens before a single word is translated.

Every clinical document goes through our Six-Gate QC process, which includes physician-led medical review, regulator-specific terminology validation, and cross-document consistency checks. We guarantee First-Pass Acceptance: if a regulator issues an RFI on a translation we delivered, we fix it at no additional cost.

We cover 8 LATAM regulators and translate between English, Spanish, and Portuguese with full regulatory context for each jurisdiction.

The result is that our clients do not lose time to translation-triggered RFIs. The submission goes in clean the first time.

If your translation vendor has never seen an RFI from the specific regulator reviewing your submission, they cannot prevent one. Regulatory translation in LATAM is a specialization, not a commodity. The vendor's cost per word is the least important number in the decision.

The most important number is how many days you lose when the regulator sends it back.